Array Biopharma To Present at the Morgan Stanley Global Healthcare Conference and the Stifel Healthcare Conference

BOULDER, Colo., Sept. 4, 2013 /PRNewswire/ -- Array BioPharma Inc. (Nasdaq: ARRY) today announced that its Chief Executive Officer, Ron Squarer, will present at the Morgan Stanley Global Healthcare Conference in New York and the Stifel Healthcare Conference in Boston. The public is welcome to participate in the conferences through webcasts on the Array BioPharma website: www.arraybiopharma.com.   

(Logo: http://photos.prnewswire.com/prnh/20121029/LA02195LOGO)

About Array BioPharma
Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer. Array is evolving into a late-stage development company and currently expects significant progress toward generating data to support our upcoming Phase 3 / pivotal trial decisions.   Novartis began a Phase 3 trial evaluating Array-invented MEK162 in patients with NRAS-mutant melanoma in July 2013 and expects to begin a Phase 3 trial in patients with BRAF-mutant melanoma in 2013.  In addition, Array began a Phase 3 trial evaluating MEK162 in patients with low-grade serous ovarian cancer under the license agreement with Novartis in June 2013.  AstraZeneca began a pivotal trial with Array-invented selumetinib in patients with thyroid cancer in May 2013 and expects to begin a Phase 3 trial in patients with non-small cell lung cancer in 2013.  Three other Array-invented drugs are also approaching Phase 3 or pivotal trial decisions which are expected by the end of 2013. These include Array's wholly-owned drugs, ARRY-520 and ARRY-614, and one partnered program, danoprevir (with InterMune/Roche).  For more information on Array, please go to www.arraybiopharma.com.

Tricia Haugeto
Array BioPharma Inc.
303-386-1193
thaugeto@arraybiopharma.com

SOURCE Array BioPharma Inc.